On one hand, PCSK9 could downregulate the expression of major histocompatibility complex-I (MHC-I) molecules on the surface of tumor cells through lysosomal degradation and downregulate tumor-infiltrating cytotoxic T lymphocytes (CTLs) [16]. The gene discussed is PCSK9; the disease is neoplasm.